{"corpus_id":58182257,"paper_sha":"37b62c35f0c8ce62f5e955b0497fda8ea67c257b","doi":"10.4103/1011-4564.181522","arxiv_id":null,"pmid":null,"pmcid":null,"mag_id":2344139181,"dblp_id":null,"acl_id":null,"title":"Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study","year":2016,"publication_date":"2016-03-01","venue":"","journal":{"name":"Journal of Medical Sciences","pages":"68 - 74","volume":"36"},"journal_issn":null,"journal_title":null,"publication_types":[],"pubmed_pub_types":null,"s2_fields_of_study":["Medicine"],"reference_count":0,"citation_count":4,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":1,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background: Zolpidem has been increasingly used in patients with sleep disorder due to its minimal respiratory depressor effects and short half-life. Materials and Methods: Recent case reports indicate that zolpidem usage may be associated with increased cancer mortality. This study aimed to determine the impact of zolpidem usage on the risk of incident cancer events in sleep disorder patients over a 3-year follow-up. Of the 6924 subjects diagnosed with sleep disorder in 2004, 1728 had used zolpidem. A Cox proportional hazard model was performed to estimate 3-year cancer event-free survival rates for patients using zolpidem and those not using it, after adjusting for confounding and risk factors. Results: At the end of follow-up, 56 patients had incident cancers, 26 (1.5%) who used zolpidem, and 30 (0.6%) who did not. After adjustments for gender, age, comorbidities, and other medications, patients using zolpidem had a 1.75 times (95% confidence interval [CI], 1.02–3) greater risk of cancer events than those not using zolpidem during the 3-year follow-up. Greater mean daily dose and longer use were associated with increased risk. Among patients with sleep disorder, mean daily dose >10 mg and length of drug use >2 months was associated with 3.74 times greater risk (95% CI, 1.42–9.83; P = 0.008) of incident cancer events. Conclusions: In this study, zolpidem use increased cancer events risk in sleep disorder patients. Risks and benefits of chronic zolpidem usage should be explained to sleep disorder patients, and long-term use should be monitored.","claims":[{"public_id":"cl_14f095e0de032a2871e0296fa1616f7e","status":"active","text":"A mean daily dose greater than 10 mg and use longer than 2 months were associated with a 3.74-fold higher risk of incident cancer events in patients with sleep disorder.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_14f095e0de032a2871e0296fa1616f7e"},{"public_id":"cl_d4de131a7566ccd72a806d1f88ea4806","status":"active","text":"Higher mean daily dose and longer duration of zolpidem use were associated with increased cancer risk.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d4de131a7566ccd72a806d1f88ea4806"},{"public_id":"cl_bd47a75014f17c260552dcb4adfcecfa","status":"active","text":"Zolpidem use was associated with a 1.75-fold higher risk of incident cancer events over 3 years in patients with sleep disorder after adjustment for gender, age, comorbidities, and other medications.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_bd47a75014f17c260552dcb4adfcecfa"}],"concepts":[{"public_id":"co_08437a3e90cf3291a2ace4f2a071be81","status":"active","name":"mean daily dose greater than 10 mg","description":"A zolpidem exposure category defined by average daily intake above 10 milligrams.","types":["exposure category"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_08437a3e90cf3291a2ace4f2a071be81"},{"public_id":"co_16792c8b5143ac577f50a3227b8a2fd7","status":"active","name":"other medications","description":"Concomitant drugs included as adjustment factors in the analysis.","types":["covariate"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_16792c8b5143ac577f50a3227b8a2fd7"},{"public_id":"co_437369c5934242008cd82b5b2195f4f0","status":"active","name":"3-year follow-up","description":"The three-year observation period used to assess cancer outcomes.","types":["study period"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_437369c5934242008cd82b5b2195f4f0"},{"public_id":"co_458d5e13b149a53153472b57256eb353","status":"active","name":"comorbidities","description":"Additional coexisting medical conditions included as adjustment factors in the analysis.","types":["covariate"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_458d5e13b149a53153472b57256eb353"},{"public_id":"co_490988931da04fbc5b8fa1b9a64fea8f","status":"active","name":"mean daily dose","description":"The average amount of zolpidem taken per day.","types":["exposure measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_490988931da04fbc5b8fa1b9a64fea8f"},{"public_id":"co_49d735353209c55c1c7b72b46503b9a3","status":"active","name":"length of drug use greater than 2 months","description":"A zolpidem exposure category defined by use lasting longer than two months.","types":["exposure category"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_49d735353209c55c1c7b72b46503b9a3"},{"public_id":"co_4e808fee884944b33161aeed6b08b8dc","status":"active","name":"duration of drug use","description":"The length of time zolpidem was used.","types":["exposure measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4e808fee884944b33161aeed6b08b8dc"},{"public_id":"co_58e1a9e54c6f81e2ab70c6a14dec5c21","status":"active","name":"incident cancer events","description":"Newly diagnosed cancer cases observed during follow-up.","types":["outcome"],"aliases":["cancer events"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_58e1a9e54c6f81e2ab70c6a14dec5c21"},{"public_id":"co_768505f7d89138f2b311af0b0f3b0058","status":"active","name":"sleep disorder","description":"A diagnosed condition characterized by abnormal sleep patterns or difficulty sleeping.","types":["condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_768505f7d89138f2b311af0b0f3b0058"},{"public_id":"co_c2562e675de50009ab1bf24eb114b5c6","status":"active","name":"age","description":"A demographic variable used as an adjustment factor in the analysis.","types":["covariate"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c2562e675de50009ab1bf24eb114b5c6"},{"public_id":"co_d16ab246443682140c24fd75d0ef045a","status":"active","name":"gender","description":"A demographic variable used as an adjustment factor in the analysis.","types":["covariate"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d16ab246443682140c24fd75d0ef045a"},{"public_id":"co_e377994cbaa8601beb1491eef0c08b6e","status":"active","name":"Cox proportional hazard model","description":"A survival analysis method used to estimate hazard ratios over time.","types":["statistical method"],"aliases":["Cox model"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e377994cbaa8601beb1491eef0c08b6e"},{"public_id":"co_e92d9e09c0aa40ed7b5c680c2b29e222","status":"active","name":"zolpidem","description":"A short-acting sedative-hypnotic drug used for sleep disorders.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e92d9e09c0aa40ed7b5c680c2b29e222"}],"external_ids":{"DOI":"10.4103/1011-4564.181522","ArXiv":null,"PubMed":null,"PubMedCentral":null,"MAG":2344139181,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/58182257","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"unknown","references_indexed":false,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":1},"paper_id":635533,"paper_uid":"76024cb9-2c0f-45f1-ba6f-374809a19f08","canonical_identity":{"paper_id":635533,"paper_uid":"76024cb9-2c0f-45f1-ba6f-374809a19f08","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/58182257"}